Search
Wisconsin Paid Clinical Trials
A listing of 1280 clinical trials in Wisconsin actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1117 - 1128 of 1280
Wisconsin is currently home to 1280 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Trial
Crohn's Disease Clinical Study
Recruiting
Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.
Conditions:
Crohn's Disease
Crohn Disease
Crohns Disease
Crohn's Disease (CD)
Crohn Colitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
Recruiting
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant endocrine therapy (AET).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Breast Cancer
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Recruiting
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: SSM Health Cancer Care, Madison, Wisconsin
Conditions: Metastatic Cancer
TRAQinform Assessment of Immunotherapy Response
Recruiting
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Melanoma
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/29/2024
Locations: Spaulding Clinical Research, West Bend, Wisconsin
Conditions: Alzheimer's Disease
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Recruiting
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD... Read More
Gender:
ALL
Ages:
Between 6 months and 34 years
Trial Updated:
07/29/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Sickle Cell Disease
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Recruiting
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Conditions: Glioblastoma, IDH-Wildtype
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Recruiting
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: Froedtert Hospital & The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)
Recruiting
The investigators will perform a feasibility/pilot trial of two non-pharmacological interventions for ADHD in college students.
Gender:
ALL
Ages:
Between 18 years and 23 years
Trial Updated:
07/26/2024
Locations: University of Wisconsin-Madison, Waisman Center, Madison, Wisconsin
Conditions: Attention Deficit Hyperactivity Disorder
CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
Recruiting
This is a single-center, open-label, phase I study designed to determine the maximum tolerated dose (MTD) and safety profile of CPI-613® when used concomitantly with chemoradiation for local control of pancreatic adenocarcinoma (PDAC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Pancreas Adenocarcinoma
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis
Recruiting
The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.
Gender:
ALL
Ages:
Between 2 months and 17 years
Trial Updated:
07/25/2024
Locations: Milwaukee (MCW): Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Shock, Septic
Storytelling and Mindfulness for Graduate Student Wellbeing
Recruiting
The purpose of this study is to evaluate an intervention for improving Science, Technology, Engineering, and Math (STEM) graduate student wellbeing. Participants will be recruited from the University of Wisconsin-Madison graduate student body. Data will be collected from participants for up to 2 years, and the investigators anticipate that the study will last for 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: Wisconsin Institute for Discovery, Madison, Wisconsin
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Recruiting
This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2024
Locations: CIBMTR, Milwaukee, Wisconsin
Conditions: Leukemia/Lymphoma, Cutaneous T Cell Lymphoma, ATLL